KDR and nonpapillary renal cell carcinoma: In an ongoing multi-center, open label phase 1/1b trial involving 109 patients with advanced solid tumor malignancies treated with sitravatinib, 20 ccRCC patients were identified that received VEGFR TKIs either once (48%), twice (24%), three-times (17%), or four-times (3%) [41].